A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants

Assessment of the Relative Bioavailability of ABBV-932 Formulations in Healthy Adult Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06849791

Enrollment

Registered

2025-02-27

Start date

2025-02-26

Completion date

2026-05-08

Last updated

2026-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteer

Keywords

Healthy Volunteer

Brief summary

This study will assess the relative bioavailability and effect of food on pharmacokinetics of ABBV-932 oral administration in healthy adult participants.

Interventions

DRUGABBV-932

Oral Capsule

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Body Mass Index (BMI) ≥ 18.0 to ≤ 32.0 kg/m\^2 after rounding to the tenths decimal at the time of screening and upon initial confinement. BMI is calculated as weight in kg divided by the square of height measured in meters. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG

Exclusion criteria

* History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness. * History of any clinically significant sensitivity or allergy to any medication or food.

Design outcomes

Primary

Measure	Time frame	Description
Maximum Plasma Concentration (Cmax) of ABBV-932	Up to approximately 6 days	Cmax of ABBV-932
Time to Cmax (Tmax) of ABBV-932	Up to approximately 6 days	Tmax of ABBV-932
Terminal Phase Elimination Rate Constant (Beta) of ABBV-932	Up to approximately 6 days	Terminal phase elimination rate constant (beta) of ABBV-932
Terminal Phase Elimination Half-Life (t1/2) of ABBV-932	Up to approximately 6 days	Terminal phase elimination half-life of ABBV-932
Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932	Up to approximately 6 days	AUCt of ABBV-932
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932	Up to approximately 6 days	AUCinf of ABBV-932
Number of Participants Experiencing Adverse Events	Up to approximately 180 days	An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Countries

United States

Contacts

STUDY_DIRECTORABBVIE INC.

AbbVie

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 5, 2026